Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BlackRock Health Sciences Opportunities Portfolio is an actively managed mutual fund that focuses on the health sciences sector. Its primary objective is long-term capital growth by investing at least 80% of its assets in equity securities—mainly common stocks—of companies involved in health sciences and related industries. These industries span biotechnology, pharmaceuticals, health care equipment and supplies, and health care providers and services. The fund often maintains a concentrated portfolio, with a significant portion of its assets in its top ten holdings, which typically include major industry leaders such as Eli Lilly, UnitedHealth Group, AbbVie, and Boston Scientific. While predominantly invested in U.S. companies, the portfolio may also include select international firms, offering additional sector diversification. It is managed by BlackRock’s team, which utilizes both fundamental research and a disciplined investment process to identify companies poised for above-average growth or trading below their intrinsic value. By focusing on innovation and long-term industry trends, the fund plays a pivotal role in providing sector-specific exposure for investors seeking participation in the evolving health care landscape.
$41.55
+$0.83 (+2.04%)
EOD Jun 25, 2026 · Twelve Data
Revenue grew 222.1%, still solid. Free cash flow declined 17% despite revenue growth, conversion is weakening.
Free cash flow declined 17% versus the prior year, cash generation momentum has weakened.
7.8x earnings, 11.0x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$78M
▲ +222.1% YoY
Net Income (TTM)
$77M
▲ +228.2% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
$55M
▼ -16.7% YoY
Op. Cash Flow (TTM)
$78M
▲ +18.5% YoY
Net Debt
-$548.00
Net Cash Position
Cash & Equiv.
$548.00
Continue Research
At a P/E of 7.8 and a price-to-free-cash-flow of 11.0, BlackRock Health Sciences Opportunities Portfolio (BME) trades below a two-stage DCF intrinsic value of about $186.03 per share, so at $41.55 the stock looks undervalued (347.7% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BlackRock Health Sciences Opportunities Portfolio scores 49/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 6.8%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $186.03 per share for BME, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $139.52. At today's $41.55, that puts the stock about 347.7% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
BlackRock Health Sciences Opportunities Portfolio scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a mixed business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, BlackRock Health Sciences Opportunities Portfolio pays a regular dividend of about $2.82 per share per year (typically in quarterly installments), a yield of roughly 6.8% at the current price. That is a payout ratio of about 52.8% of earnings, so the dividend is well covered. BlackRock Health Sciences Opportunities Portfolio has grown the dividend at roughly 8.8% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For BME's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. BME currently trades below its estimated intrinsic value and scores 49/100 on quality (mixed). It also yields about 6.8%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.